Main Article Content


The purpose of the current investigation is to determine whether Morinda reticulate can prevent obesity in neonatal rats that has been brought on by monosodium glutamate (MSG). Newborn neonatal rats used in the trials received intraperitoneal injections of 2 mg/g and 4 mg/g of MSG on the second, fourth, and sixth postnatal days, respectively. At the age of 65 days, ethanolic extract (EE) and acetone extract (AE) of M. reticulate were given in doses of 100 and 200 mg/kg, p.o./day. Body weight, activity level, core body temperature, and a number of biochemical indicators including serum glucose, total cholesterol, triglyceride levels, and organ weights were all measured on day 60 of treatment. After receiving extract treatment, there was a considerable decrease in body weight, an increase in body temperature, and locomotor activity. In comparison to MSG-control rats, M. reticulate dramatically boosted high density lipoprotein (HDL), lowered total cholesterol and triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels in the serum. In MSG-induced obese rats, M. reticulate extracts demonstrated an antihyperlipidemic impact and anti-obesity capabilities.


Monosodium glutamate, Neonatal, obesity, Antihyperlipidemic, Morinda reticulate,

Article Details